RXi Pharmaceuticals Corporation (NASDAQ:RXII) announces the completion of enrollment in its Phase 1/2 study assessing RXI-109-1501 for the treatment of patients with advanced neovascular or 'wet' age-related macular degeneration where retinal scarring can result in continued vision loss.
The primary endpoint is safety and tolerability. According to ClinicalTrials.gov, the estimated completion date is September.
RXI-109 is a self-delivering RNAi (sd-rxRNA) compound developed to target connective tissue growth factor, a key regulator of scar formation.
Subscribe for full text news in your inbox